Biotechnology

Antengene to Participate in Three Upcoming Investor Conferences in May/June

CICC Healthcare Industry Forum 2022: May 9th to 12th BTIG Virtual China Biotech Day: June 1st Citi's 3rd Pan-Asia Regional Investor Conference 2022: June 8th to June 10th SHANGHAI and HONG KONG, May 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading inno...

2022-05-06 08:30 2505

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 5, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, is pleased to announce the appointment o...

2022-05-06 08:00 1868

Insilico Medicine expands synthetic lethality portfolio with the nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

NEW YORK, May 6, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...

2022-05-06 05:00 2556

Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

NEW YORK, May 5, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...

2022-05-05 23:00 2571

HOYA Vision Care Releases Results of First of its Kind Six-Year MiYOSMART Spectacle Lens Follow-up Clinical Study

Strong evidence shows continued long-term lens effectiveness in slowing myopia progression in children BANGKOK, May 5, 2022 /PRNewswire/ -- HOYA Vision Care, a leader in optical technology innovation, shared the results of asix-year follow-up clinical study on its award winning MiYOSMART spectac...

2022-05-05 22:12 3019

TIKOMED and IQVIA announce a strategic collaboration for the development of TIKOMED's lead drug platform candidate ILB®

VIKEN, Sweden, May 5, 2022 /PRNewswire/ -- Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative p...

2022-05-05 20:40 1435

Mediso acquires nuclear medicine supplier Bartec Technologies

FARNBOROUGH, England, and BUDAPEST, Hungary, May 5, 2022 /PRNewswire/ -- Mediso Ltd today announced the acquisition of Bartec Technologies Ltd, UK based company specialised in the supply, installation and support of Nuclear Medicine and Molecular Imaging equipment and accessories. The acquisition...

2022-05-05 06:38 2100

Kintor Pharma Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma

SUZHOU, China, May 4, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing inthe United States of its multi-regional pha...

2022-05-04 20:36 2142

Nanoform launches "STARMAP® Online" placing AI-power at the fingertips of medicine developers

HELSINKI, May 4, 2022 /PRNewswire/ -- Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company, today announced that it has launched its sparse-data AI solution (STARMAP® Online) as a secure online portal for direct use by its current and future partners. Since its inception i...

2022-05-04 14:35 1820

Prenetics Reports Record First Quarter 2022 Preliminary Financial Results. Nasdaq Listing in Partnership with Artisan Acquisition Corp. Expected on May 18, 2022[1]

Continues to Deliver Strong Results and Significant Growth   First Quarter 2022 Highlights * Revenue for the first quarter of 2022 was US$92.0 million, a record high, compared to US$57.5 million in the first quarter of 2021 * (Loss)/profit from operations under IFRS was US$(0.6) million in ...

2022-05-04 09:05 2598

Why Scaleups like Sophie's Bionutrients are Flocking to Food (not Silicon) Valley

Biotech Scaleup Sophie's Bionutrients Celebrates Earth Day and Six Months in Europe's "Food Valley" WAGENINGEN, Netherlands, May 3, 2022 /PRNewswire/ -- Six months ago, micro-algae protein pioneer Sophie's Bionutrients decided to move itsSingapore headquarters to the global alt-protein hotspot ...

2022-05-03 23:33 5587

Servatus strengthens Board with appointment of biopharmaceutical division head at Boehringer Ingelheim, Dr Uwe Buecheler

* New Board appointment deepens and consolidates Servatus' extensive commercial and scientific expertise for its global biotherapeutics programs * Dr Buecheler joins as Non-Executive Director from leading pharmaceutical giant Boehringer Ingelheim inGermany, where he is both Senior Vice Preside...

2022-05-02 07:36 3143

Asia Pacific Initiative on Reproduction (ASPIRE) 2022 Congress: Recognising the 'tip of the iceberg' in the complex and chronic effects of endometriosis

SINGAPORE, May 1, 2022 /PRNewswire/ -- Leaders in reproductive medicine from more than 100 countries were today urged to help prevent women suffering from the debilitating effects of endometriosis from embarking on "diagnostic misadventures." Speaking at the 2022 Congress of the Asia Pacific I...

2022-05-01 16:00 9656

Asia Pacific Initiative on Reproduction (ASPIRE) 2022 Congress: Linking male infertility diagnosis with the window to future health trajectories

SINGAPORE, May 1, 2022 /PRNewswire/ -- Male infertility factors are emerging as likely biomarkers for later life health events including hospital treatments and possible premature death from conditions such as cancer, cardiovascular and metabolic diseases. Lifestyle and social factors, includi...

2022-05-01 13:30 4826

Inmagene Receives FDA's IND Clearance for OX40 Antagonist

SAN DIEGO and SHANGHAI and SYDNEY, April 30, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announces that the U.S. Food and Drug Administration (FDA) has cleared drug candidate IMG-007, a monoclonal antibody against OX40, to proceed to Phase I clinical development. Inmagene is de...

2022-05-01 06:00 3593

Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights

HONG KONG, April 30, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced today that the Company will acquire 100% ...

2022-04-30 04:16 9214

Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting

SHANGHAI and HONG KONG, April 29, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onc...

2022-04-29 22:30 2794

Biocytogen Enters into Antibody Agreement with Merck

BEIJING, April 29, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck to grant them a sole license to evaluate Biocytogen's proprietary antibodies against at least three distinct targets...

2022-04-29 20:00 2532

Promising COVID oral antiviral being co-researched by Healion Bio and FUJIFILM Toyama

FREDERICK, Md., April 29, 2022 /PRNewswire/ -- Healion Bio, a closely held biotechnology company, today announced a collaborative agreement to research a combination antiviral against SARS-CoV-2 and other deadly pathogens. The combination will include one of Healion Bio's protease inhibitors and ...

2022-04-29 01:00 2157

Gracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting

Gracell to present longer-term follow-up clinical data evaluating GC012F, an autologous CAR-T therapeutic candidate dual-targeting BCMA and CD19, for the treatment of relapsed/refractory multiple myeloma SAN DIEGO, Calif. and SUZHOU, China, April 28, 2022 /PRNewswire/ -- Gracell Biotechnologies ...

2022-04-28 22:30 1855
1 ... 140141142143144145146 ... 281